• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DarioHealth Announces CFO Transition

    4/21/25 8:30:00 AM ET
    $BNRG
    $DRIO
    $PLUR
    Building Products
    Industrials
    Medical/Dental Instruments
    Health Care
    Get the next $BNRG alert in real time by email

    NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025.

    DarioHealth Corp. Logo

    The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity.

    "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished," said Mr. Ben-David. "I am confident in Chen's ability to lead the Company's financial strategy and contribute to its continued growth."

    Mrs. Franco-Yehuda brings extensive financial leadership experience, with a strong background in corporate finance, capital markets, and strategic growth initiatives. She has held senior financial leadership roles across publicly traded companies in the healthcare and life sciences sectors. Combining deep knowledge of healthcare business models with a sharp understanding of capital markets, her experience uniquely positions her to lead Dario's financial organization through its next phase of growth and expansion.

    Prior to joining Dario, she most recently served as Chief Financial Officer, Treasurer, and Secretary at Pluri Inc. (Nasdaq, TASE: PLUR), a global biotech company, where she led financial strategy, investor relations, legal affairs, and significant cross-border transactions. She played an instrumental role in securing substantial capital through multiple public and private fundraising rounds, executing non-dilutive funding agreements and driving merger and acquisition activity. In recognition of her accomplishments, she was awarded the Israeli CFO Excellence Award in January 2025.  

    Chen's early career started as Audit/Assurance Manager at PwC. She is a licensed CPA in Israel and holds a bachelor's degree in accounting and economics from the University of Haifa, with high honors. She also sits on the board of Brenmiller Energy (NASDAQ:BNRG) where he is an audit committee and compensation committee member.

    "On behalf of the Board and the entire team at DarioHealth, I would like to express our gratitude to Zvi for his dedication and contributions to the Company," said Erez Raphael, CEO of DarioHealth. "During his tenure, Zvi played a key role in the Company's transformation from a single-condition solution provider into one of the most comprehensive multi-condition digital health platforms in the industry. His financial stewardship supported our strategic expansion across diabetes, hypertension, mental health, weight management, and musculoskeletal care, helping to position Dario as a leader in digital health. We look forward to welcoming Chen and leveraging her expertise as we continue to drive innovation and growth."

    About DarioHealth Corp. 

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. 

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

    Cautionary Note Regarding Forward-Looking Statements 

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

    DarioHealth Corporate Contact

    Mary Mooney

    VP Marketing

    [email protected]

    +1-312-593-4280 

    DarioHealth Investor Relations Contact 

    Kat Parrella

    Investor Relations Manager 

    [email protected]

    +315-378-6922 

    Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-announces-cfo-transition-302433262.html

    SOURCE DarioHealth Corp.

    Get the next $BNRG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNRG
    $DRIO
    $PLUR

    CompanyDatePrice TargetRatingAnalyst
    DarioHealth Corp.
    $DRIO
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    DarioHealth Corp.
    $DRIO
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    DarioHealth Corp.
    $DRIO
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    DarioHealth Corp.
    $DRIO
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $BNRG
    $DRIO
    $PLUR
    SEC Filings

    See more
    • SEC Form 6-K filed by Brenmiller Energy Ltd

      6-K - Brenmiller Energy Ltd. (0001901215) (Filer)

      6/17/25 9:15:03 AM ET
      $BNRG
      Building Products
      Industrials
    • SEC Form POS AM filed by Brenmiller Energy Ltd

      POS AM - Brenmiller Energy Ltd. (0001901215) (Filer)

      6/13/25 4:18:02 PM ET
      $BNRG
      Building Products
      Industrials
    • SEC Form 6-K filed by Brenmiller Energy Ltd

      6-K - Brenmiller Energy Ltd. (0001901215) (Filer)

      6/9/25 8:38:55 AM ET
      $BNRG
      Building Products
      Industrials

    $BNRG
    $DRIO
    $PLUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • DarioHealth downgraded by TD Cowen with a new price target

      TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      1/29/25 7:36:04 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

      5/13/22 9:01:42 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Aegis Capital reiterated coverage on DarioHealth with a new price target

      Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

      1/26/22 10:35:44 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $BNRG
    $DRIO
    $PLUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

      Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer an

      5/15/25 7:00:00 AM ET
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DarioHealth Reports First Quarter 2025 Financial and Operating Results

      First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5

      5/14/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $BNRG
    $DRIO
    $PLUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Franco-Yehuda Chen was granted 500,000 shares (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:02:48 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Franco-Yehuda Chen

      3 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:01:27 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

      3 - DarioHealth Corp. (0001533998) (Issuer)

      3/7/25 4:05:19 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $BNRG
    $DRIO
    $PLUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      11/14/24 4:15:15 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/12/24 4:37:42 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/10/24 6:00:13 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $BNRG
    $DRIO
    $PLUR
    Leadership Updates

    Live Leadership Updates

    See more
    • DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

      Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

      2/27/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Brenmiller Europe S.L. Appoints Emilio Lopez, Visionary Renewable Energy Executive, as Chairman of its Board

      Dr. José Luis Morán, leads Brenmiller Europe as Managing Director; he additionally is the Director of Integrated Energy Solutions for Green Enesys and Viridi, Brenmiller Energy's joint venture partners Spain-based Brenmiller Europe S.L. established to accelerate commercial rollout of bGen™ thermal energy storage technology across Europe where the regulatory, project financing, and clean energy cost-benefit environment is highly supportive of rapid commercial adoption of TES systems Brenmiller Energy Ltd. ("Brenmiller", "Brenmiller Energy" or the "Company") (NASDAQ:BNRG), a leading global energy provider of thermal energy storage ("TES") solutions to industrial and utility customers,

      12/26/24 8:30:00 AM ET
      $BNRG
      Building Products
      Industrials
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $BNRG
    $DRIO
    $PLUR
    Financials

    Live finance-specific insights

    See more
    • DarioHealth Reports First Quarter 2025 Financial and Operating Results

      First quarter revenue of $6.75 million, a 17% increase year-over-year, driven by employer and health plan (B2B2C) growth, and a decrease of 11% sequentially.Gross margin increased to 57.5% compared to 42.2% in the first quarter of 2024Gross margin (non-GAAP) increased to 70.5%, up from 62.4% in the first quarter of 2024Operating expenses decreased by 35% compared to the first quarter of 2024 and 16% sequentially, with additional efficiencies anticipated through ongoing AI-driven process optimizationGAAP operating loss decreased by 47% compared to the first quarter of 2024, improving to $9.4 millionNon-GAAP operating loss decreased by 36% compared to the first quarter of 2024, improving to $5

      5/14/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results

      Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas

      3/10/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $BNRG
    $DRIO
    $PLUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      12/13/24 4:05:12 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

      SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

      12/5/24 11:18:20 AM ET
      $BNRG
      Building Products
      Industrials
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      10/29/24 11:45:28 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care